drugset / Trial / NCT06998719
Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC
Phase 2
Not yet recruiting
80 enrolled
Bi Nan
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A Phase II, interventional study of neoadjuvant durvalumab (MEDI 4736) and platinum-based Chemotherapy, followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab, in participants with borderline resectable stage III Non-small Cell Lung Cancer (NSCLC) (ACCESS)
Timeline
- Start
- 2025-07
- Primary completion
- 2026-05
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |